Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E Lowenthal, the President and CEO of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on July 16, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions at weighted average prices of $11.4028 and $11.4031.
• Following the transactions, Lowenthal directly owns 4,315,313 shares.
• Lowenthal also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, the Richard Lowenthal Charitable Remainder UniTrust, and shares held by his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.

Industry Context

Insider sales are a common occurrence in publicly traded companies. Rule 10b5-1 plans allow insiders to sell shares at predetermined times and prices to avoid accusations of trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although sales under 10b5-1 plans are usually anticipated.

Key Dates